Furthermore, novel candidate drugs for CML BC such as vascular endothelial growth factor receptor (VEGFR) and nicotinamide phosphoribosyltransferase (NAMPT) inhibitors were discovered from the DSRT analysis. Here, NAMPT is linked to chronic myelogenous leukemia, BCR-ABL1 positive.